Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clene Inc (NQ: CLNN ) 5.760 -0.350 (-5.73%) Streaming Delayed Price Updated: 3:11 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Clene Inc < Previous 1 2 3 4 5 Next > BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership October 24, 2024 Via Investor Brand Network Exposures Product Safety Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences October 18, 2024 Via Investor Brand Network Toxic Protein Could Be Behind the Development of Amyotrophic Lateral Sclerosis October 18, 2024 Via Investor Brand Network Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements October 10, 2024 Via Investor Brand Network BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences October 09, 2024 Via Investor Brand Network Disruptions in Purine Metabolism Cited in Parkinson’s Development October 02, 2024 Via Investor Brand Network Researchers Identify New Gene Behind ALS Onset July 29, 2024 Via Investor Brand Network BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M October 02, 2024 Via Investor Brand Network Exposures Product Safety IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements October 02, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M September 30, 2024 Via Investor Brand Network IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership September 26, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures Product Safety Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership September 24, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8 September 16, 2024 Via Investor Brand Network Exposures Product Safety Does Multiple Sclerosis Reduce Risk of Developing Dementia? September 11, 2024 Via Investor Brand Network Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference September 11, 2024 Via Investor Brand Network Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets September 06, 2024 Via Investor Brand Network BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 Via Investor Brand Network BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases August 30, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast August 28, 2024 Via Investor Brand Network Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials August 22, 2024 Via Investor Brand Network Exposures Product Safety UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis August 19, 2024 Via Investor Brand Network Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease August 12, 2024 Via Investor Brand Network Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions August 12, 2024 Via Investor Brand Network BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode August 08, 2024 Via Investor Brand Network BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates August 07, 2024 Via Investor Brand Network Exposures Product Safety BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA August 06, 2024 Via Investor Brand Network Exposures Product Safety Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics August 06, 2024 Via Investor Brand Network BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase August 05, 2024 Via Investor Brand Network Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast July 26, 2024 Via Investor Brand Network Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature July 23, 2024 Via Investor Brand Network < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
